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specific. Except for preschoolers, therapeutic management of patients with ADHD 
relied heavily on drug treatment.
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Objectives: To measure the change in the risk of first, second, and third hospitali-
zation and the change in the proportion of hospitalization-free men and women 
above the age of 60 living in Stockholm and Uppsala counties in Sweden between 
1972 and 2010. MethOds: Individuals were followed in national registers for hos-
pitalizations and deaths from all causes between 1972 and 2010. Censoring occured 
at whichever of the following events appeared first; hospitalization (first, second, 
thrid), death, or December 31, 2010. Survival analysis was used to determine the 
proportion of hospitalization-free individuals. Discrete time logistic regression 
was used to obtain the the relative risk (RR) of first, second and third hospitaliza-
tion. Results: An increase in the proportion of hospitalization-free individuals over 
time was observed for both men and women; for example 87% more 82 year-old 
men, born in 1928, were free of hospitalizations since the age of 60 compared to 
those born in 1912. Between the years 1972 and 2010, the average annual decrease 
in the risk of first hospitalization after the age of 60 was 1% for both men (RR: 
0.991, 95%CI: 0.991-0.992) and women. The average annual risk for hospitalization 
decreased for the second and thrid event as well; however the reduction was not 
significant. cOnclusiOns: With the increase in the proportion of elderly in the 
population, the number of individuals with chronic diseases may increase, leading 
to higher demand for medical and social care. We have observed downward trends of 
the risk of first, second, and third hospitalization after the age of 60, which could be 
explained by a postponement of severe morbidity to higher ages. Focus on primary 
care and changes in inpatient care in Sweden may also partly exaplain the annual 
reduction in the risk of hospitalization.
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Objectives: Since the implementation of Pediatric Regulations/Legislations in the 
USA (Pediatric Research Equity Act - PREA) and in Europe (Pediatric Investigation 
Plans - PIPs), product development programs should include pediatric studies. The 
objective of this study is to review opinions (EMA) and requirements (FDA) given by 
both agencies in the case of sitagliptin (alone and combined) for the treatment of 
diabetes mellitus in children. MethOds: The EMA and FDA websites were explored 
to: 1) Identify the products marketed under the INN of sitagliptin (alone or in com-
bination), and 2) Identify the associated PIPs or PREA requirements. The search was 
performed on January 18, 2013. Results: Eight products were marketed in Europe 
[i.e., sitagliptin (Januvia, Ristaben, Tesavel, Xelvia) and sitagliptin + metformin 
(Janumet, Efficib, Ristfor, Velmetia)]. Four products were authorized in the USA [i.e., 
sitagliptin (Januvia); sitagliptin + metformin (Janumet, Janumet XR); sitagliptin + 
simvastatin (Juvisync)]. The FDA and the EMA provided the same opinion for sitag-
liptin alone, i.e., deferred pediatric study for patients aged 11 to 16. The FDA and the 
EMA disagreed on sitagliptin + metformin. The EMA granted a waiver for all subsets 
of the pediatric population on the grounds that the specific medicinal product does 
not represent a significant therapeutic benefit over existing treatments, while the 
FDA required a pediatric study under PREA for the treatment of type 2 diabetes in 
pediatric patients aged 11 to 16. As for sitagliptin + simvastatin, the FDA grants a 
waiver on the grounds that the product does not represent a meaningful therapeutic 
benefit over existing therapies for pediatric patients. cOnclusiOns: The FDA and 
the EMA have similar opinions except for the combination sitagliptin + metformin. 
One reason could be the higher prevalence of type 2 diabetes mellitus in children 
in the USA as compared to Europe.
InfecTIon – clinical outcomes studies
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Objectives: The objective of the present study was to assess the geographic cor-
relation between the incidence of Lyme disease (LD) and mortality due to certain 
degenerative neurologic diseases (DND) in the US. MethOds: For this ecological 
study, public data sources at the CDC were queried to quantify LD cases and DND 
deaths for the 5-year period 2002-2006. Alzheimer’s disease, Parkinson’s disease, 
and motor neuron disease were preselected as DND of interest. The separate 
datasets, for LD and DND, were combined by matching county and state names. 
Counties with at least 1 case of LD and at least 10 deaths due to DND were included 
in analyses. All analyses were performed in SAS. Results: Of the 3141 counties of 
the US, 1372 reported at least 1 case of LD, 2742 reported at least 10 deaths due to 
DND, and 1339 met both conditions and were therefore included in analyses. The 
observed number of LD cases and DND deaths for a single county ranged from 1- 
6407 (mean: 78; median: 3) and 10-9207 (mean: 165; median: 55), respectively. The 
Spearman rank test indicated that there is a fair degree of correlation between LD 
incidence and DND mortality (r= 0.44, p< 0.0001). In sensitivity analyses, (1) exclud-
ing outliers, defined as observations ≥ 99th percentile (LD> 53; DND> 1255), and (2) 
evaluating each disease separately, the correlation remained similar in magni-
tude and statistically significant (coefficient: 0.32-0.41; p< 0.0001). cOnclusiOns: 
There is a fair degree of correlation between LD incidence and DND mortality: 
US counties with a higher number of LD cases tend to have a higher number of 
Objectives: Anabolic-Androgenic Steroids (AAS) have been used for muscle mass 
development for over fifty years. The health outcomes of supraphysiologic doses of 
AAS have been debated, but most existing information pertains to men. This pur-
pose of the study is to use the National Longitudinal Study of Adolescent Health 
(AddHealth) to elucidate health outcomes of AAS usage in women. MethOds: 
A cohort study of female AAS users were assessed in two time periods six years 
apart. Baseline descriptive statistics were used to describe age, income, race, drug 
use, education, and work performed for the sample. Follow up health outcomes 
include diabetes, heart disease, hyperlipidemia, anger, physician visit, use of medi-
cal care in the last year, Body Mass Index (BMI), blood pressure (BP), C-reactive 
protein, and HbA1C. Each dependent variable was tested in independent logis-
tic regressions and in sensitivity tests using a MANOVA. Results: The sample 
included 49 female respondents. Education was associated with a two-fold greater 
odds of AAS use comparing those who attended vocational school to those who 
attended college (OR= 2.22, p= .03). Anger was associated with 88% greater risk of 
AAS use (OR= 1.88, p= .04). HbA1c in the pre-diabetic range, while not statistically 
significant may be associated with AAS use (OR= 1.85, p= .05). No other health 
outcomes were identified. cOnclusiOns: This study contributes to the literature 
of female AAS use showing little in health care usage and long term health conse-
quences. Anger is associated with male users but little research exists pertaining 
to this phenomenon in women. Elevated HbA1c is not commonly associated with 
AAS use, but due to the small sample size more research should assess AAS use 
among females.
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Objectives: As a basis for future safety evaluations of oral contraceptive (OC) use in 
Europe, current user and treatment characteristics were assessed in four European 
health care databases. MethOds: A descriptive retrospective database study was 
performed over 2009-2010 in GP databases from The Netherlands (IPCI), UK (THIN) 
and Italy (HSD) and linked pharmacy dispensing and hospital admission data from 
The Netherlands (PHARMO). Study follow-up started at the first OC prescription 
in 2009-2010 (users), one year after database entry or at Jan 1, 2009. Health indica-
tors at start of follow-up included BMI and previous diagnosis of, or use of drugs 
for selected chronic conditions. Also, previous diagnoses of deep vein thrombosis, 
pulmonary embolism, cerebrovascular disease, myocardial infarction, breast cancer 
and cervical cancer were assessed. Treatment characteristics of OC included his-
tory of use, type of OC (chemical substance) used during 2009-2010 and switches or 
discontinuations. Results: Among 4.9 million women, 14% had OC prescribed in 
2009-2010. In The Netherlands and UK, 12-16% and in Italy 6% had a record of OC 
use. The prevalence of OC recorded prescription at January 1, 2010 was 81 per 1000 
women of all ages and 271 per 1000 women aged 15-24, a much lower figure than 
what is recorded by surveys, probably due to switches between use and non-use 
and to reimbursement and/or prescription policies that reduce recording in GP data-
bases. Among the non-users in 2009-2010, up to 22% had a history of OC recorded 
use. Little differences in health indicators were found between users and non-users 
in the databases where the information was available. cOnclusiOns: Trends in 
health among European women in general also apply to OC users. However, OC use 
is not registered very well in health care databases which limits the possibilities 
of pharmacovigilance. Distribution channels and reimbursement policies vary, as 
well as recording in the databases.
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Objectives: To explore health care utilization and treatment patterns for atten-
tion-deficit/hyperactivity disorder (ADHD) in Germany, with particular emphasis 
on psychostimulant prescriptions. MethOds: The complete claims database of 
the organization of physicians registered with statutory health insurance (SHI) 
in Nordbaden/Germany was available for analysis, covering the total regional 
population enrolled in SHI (2.24 million lives). The dataset for years 2003 to 2009 
was reorganized as to allow patient-centered evaluation. For calendar year 2009, 
21,287 patients with ADHD (male, 15,108; female, 6,179; including 5,931 patients 
or 27.9% [male, 4,582; female, 1,349] with coexisting conduct disorder [F90.1 or a 
combination of F90 and F91 codes according to ICD-10]) were available for anal-
ysis. Results: Preschool children (age 0-5 years) with ADHD were prescribed 
medication in very rare cases (1.6% in 2009) and after an average lead time of 
more than one year only. Most received some form of nonpharmacological therapy 
or were left untreated (42%). In contrast, 41% of children (age group 6-12 years, 
since 2003, continuously increasing from 32%) and 54% of adolescents (age group 
13-17 years, rate remaining stable since 2006) were prescribed either stimulant 
(methylphenidate, MPH, or amphetamine) or nonstimulant (atomoxetine) drugs. 
Males and patients with concomitant conduct disorder were more likely to receive 
medication treatment. Modified-release MPH formulations were more widely used 
than immediate-release MPH. Overall use of medication increased steadily, from 
32.2% of ADHD patients in 2003 to 39.9% in 2009, whereas its rate decreased over 
time in adult patients (declining from 38% in 2003 to 26% in 2009). – Upon indi-
vidual review of all prescriptions of ADHD medication for members of the control 
group, no evidence was found supporting potentially inappropriate use of stimu-
lant medication. cOnclusiOns: Treatment patterns were highly age and gender 
